TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21056439

Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of home-based physical activities, health advice, and aspects of healthcare management over 15 months followed by a 3-month latent period.
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Health education intervention (compliant group)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 839
Study: 17906762

Group type: EXPERIMENTAL
Intervention: Flaxseed oil capsules 1 g/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flaxseed oil capsules 2 g/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 38
Study: 15818611

Group type: EXPERIMENTAL
Intervention: Consistently elevated perceived-deterrence scores
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Consistently low perceived-deterrence scores
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Increasing perceived-deterrence scores
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Decreasing perceived-deterrence scores
Number of subjects: 255
Study: 12414419

Group type: EXPERIMENTAL
Intervention: Swedish Interactive Threshold Algorithm (SS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full-threshold (FT)
Number of subjects: 80
Study: 10036609

Group type: EXPERIMENTAL
Intervention: 0.62 g/kg alcohol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Behavioral reinforcement (B)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 4.4 mg/kg caffeine (C)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of behavioral reinforcement and caffeine (B + C)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study: 8526788

Group type: EXPERIMENTAL
Intervention: LDL apheresis with anti‐LDL immunosorbents
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lp(a) apheresis
Number of subjects: 30
Study: 31685553

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXE Q4W)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W)
Number of subjects: 657

Group type: COMPARATOR
Intervention: 40 mg adalimumab every 2 weeks (ADA) followed by ixekizumab (ADA/IXE)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo followed by ixekizumab (PBO/IXE)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXE Q4W) in COAST-W
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W) in COAST-W
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo followed by ixekizumab (PBO/IXE) in COAST-W
Number of subjects: 657
Study: 31096515

Group type: EXPERIMENTAL
Intervention: 20 mg esomeprazole
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole
Number of subjects: 197
Study: 26882061

Group type: EXPERIMENTAL
Intervention: Topical dilute epinephrine (DE) 1% with lidocaine 1:100,000
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical phenylephrine 2.5%
Number of subjects: 41
Study: 25534490

Group type: EXPERIMENTAL
Intervention: Alprostadil liposomal preparation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study: 23760871

Group type: EXPERIMENTAL
Intervention: 10 % imidacloprid/4.5 % flumethrin collar (Seresto®, Bayer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 20
Study: 21462690

Group type: EXPERIMENTAL
Intervention: Coach approach intervention
Number of subjects: 137
Study: 19397561

Group type: EXPERIMENTAL
Intervention: Eczema workshop
Number of subjects: 99

Group type: COMPARATOR
Intervention: Dermatologist-led clinic
Number of subjects: 99
Study: 16453184

Group type: EXPERIMENTAL
Intervention: Tracing method
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 24
Study: 15365430

Group type: EXPERIMENTAL
Intervention: Medium-energy all-purpose (ME) collimator
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-energy all-purpose (LEAP) collimator
Number of subjects: 15
Study: 11407869

Group type: EXPERIMENTAL
Intervention: Dietary supplementation for 10 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (6 malnourished elderly subjects)
Number of subjects: 17
Study: 8988886

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 934

Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 934
Study: 8358112

Group type: EXPERIMENTAL
Intervention: Chloroform/methanol (CM; 2:1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ether/acetone (EA; 1:1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control site
Number of subjects: 16
Study: 3653758

Group type: EXPERIMENTAL
Intervention: Telenzepine 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Telenzepine 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pirenzepine 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Telenzepine
Number of subjects: 10
Study: 31957889

Group type: EXPERIMENTAL
Intervention: Automated assay (Galileo NEO, Immucor)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Manual gel testing
Number of subjects: 54
Study: 29721623

Group type: EXPERIMENTAL
Intervention: Educational material delivered by postal mail
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Educational material delivered by patient choice (postal mail, email, or text messaging)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group without educational material
Number of subjects: 54
Study: 26912491

Group type: EXPERIMENTAL
Intervention: 400 mg DHA/d
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 25081652

Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation (HMV)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Hospital initiation of mechanical ventilation
Number of subjects: 77
Study: 22251828

Group type: EXPERIMENTAL
Intervention: Neurocognitive habilitation therapy (group therapy intervention for foster and adoptive caregivers and their children)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 78
Study: 21077522

Group type: EXPERIMENTAL
Intervention: New method for chorion villus sampling (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional single needle technique (group 1)
Number of subjects: 0
Study: 18680574

Group type: EXPERIMENTAL
Intervention: Simple imputation procedures (last value carried forward, next value carried backward, last-and-next)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothesis test and logistic regression approaches
Number of subjects: 0
Study: 15728081

Group type: EXPERIMENTAL
Intervention: IV clonidine 1 microg/kg (group IC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: IV saline (group L)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IV saline and PCB with clonidine 1 microg/kg (group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study: 12850874

Group type: EXPERIMENTAL
Intervention: Nurse practitioner ‐ physician team
Number of subjects: 157

Group type: COMPARATOR
Intervention: Physician alone
Number of subjects: 157
Study: 10541912

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at a frequency of 4 Hz (1.0 ms(‐2) rms) for 10 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with anticholinergic (scopolamine) and alpha-adrenergic blocking agents (prazosin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with beta-adrenergic blocking agent (propranolol)
Number of subjects: 10
Study: 9084534

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg/kg/h after 0.3 mg/kg bolus injection (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg/kg/h after 0.4 mg/kg bolus injection (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol infusion at 5 mg/kg/h after 0.5 mg/kg bolus injection (Group C)
Number of subjects: 45
Study: 1879784

Group type: EXPERIMENTAL
Intervention: Materna Tsimchit
Number of subjects: 45

Group type: COMPARATOR
Intervention: Isomil
Number of subjects: 45
Study: 6980404

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (4.5 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tranexamic acid and Placebo
Number of subjects: 12
Study: 30580469

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 39
Study: 29136187

Group type: EXPERIMENTAL
Intervention: Single early intravesical instillation of pirarubicin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 310
Study: 26948548

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single-bundle (SB) technique
Number of subjects: 105
Study: 25124257

Group type: EXPERIMENTAL
Intervention: Therapeutic workplace
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 40
Study: 22516265

Group type: EXPERIMENTAL
Intervention: Gaseous cryotherapy (GC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cold pack
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cryocuff
Number of subjects: 66
Study: 20736192

Group type: EXPERIMENTAL
Intervention: Immediate or early percutaneous coronary intervention (PCI) after fibrinolysis
Number of subjects: 3325

Group type: COMPARATOR
Intervention: Deferred PCI or ischaemia-guided management
Number of subjects: 3325
Study: 18042518

Group type: EXPERIMENTAL
Intervention: 12-week moderate exercise training (60% heart rate reserve), 25-minute cycling followed by 10-minute warm-up/cool-down, 3 times a week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 matched sedentary subjects) without exercise
Number of subjects: 20
Study: 16318970

Group type: EXPERIMENTAL
Intervention: Subfreezing needles (‐14 degrees C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Room temperature needles (20‐22 degrees C)
Number of subjects: 62
Study: 12417543

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sibutramine + Metoprolol
Number of subjects: 11
Study: 10379020

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5000 IU intramuscularly three times per week for four weeks)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 807

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 807
Study: 8590162

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 848

Group type: COMPARATOR
Intervention: H2-receptor blockers (ranitidine or famotidine)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Ranitidine, famotidine, nizatidine, cimetidine, or sucralfate
Number of subjects: 848
Study: 1838397

Group type: EXPERIMENTAL
Intervention: 99mTc-hexakis 2-methoxy isobutyl isonitrile (99mTc-MIBI)
Number of subjects: 464
Study: 7067923

Group type: EXPERIMENTAL
Intervention: Repeat action tablet containing 1 mg of azatadine maleate and 60 mg of d-pseudoephedrine sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tablet of 60 mg of d-pseudoephedrine sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tablet of 1 mg of azatadine maleate
Number of subjects: 0
Study: 28891024

Group type: EXPERIMENTAL
Intervention: HFD supplemented with 0.04% RSV
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HFD supplemented with 0.36% RSV
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HFD supplemented with 1.08% RSV
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normal fat diet (NFD, 5% fat, w/w)
Number of subjects: 3

Group type: COMPARATOR
Intervention: HFD (11% fat)
Number of subjects: 3
Study: 27228369

Group type: EXPERIMENTAL
Intervention: Ovulation induction treatment
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Antral follicle count
Number of subjects: 748
Study: 26218723

Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos (PLE) supplementation after photodynamic therapy (PDT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 34
Study: 23878827

Group type: EXPERIMENTAL
Intervention: Herculite Précis (M1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tertic N‐Ceram (M2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Filtek Z350 (M3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Charisma Opal (M4)
Number of subjects: 8
Study: 20376059

Group type: EXPERIMENTAL
Intervention: Heparin (0.5 IU kg⁻¹ h⁻¹ in TPN solutions)
Number of subjects: 246

Group type: COMPARATOR
Intervention: No heparin (TPN fluids without heparin)
Number of subjects: 246
Study: 19034975

Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen and NSAIDs ingestion (group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multiple NSAIDs ingestion (group Ic)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NSAIDs ingestion (group Ib)
Number of subjects: 80
Study: 16769016

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS)
Number of subjects: 190
Study: 12707697

Group type: EXPERIMENTAL
Intervention: HA-coated components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-HA-coated components
Number of subjects: 0
Study: 11142412

Group type: EXPERIMENTAL
Intervention: Topical DFMO ointment (10% w/w) applied twice daily for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo hydrophilic ointment applied twice daily for 6 months
Number of subjects: 48
Study: 9066044

Group type: EXPERIMENTAL
Intervention: TryIPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular E-IPV
Number of subjects: 0
Study: 8104062

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 60 mg (single im injection)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms bid (aerosol spray)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Terfenadine 60 mg daily (tablets)
Number of subjects: 44
Study: 3542441

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 0.5 mg qid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30041598

Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) program plus practice facilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMS academic detailing educational intervention
Number of subjects: 0
Study: 28073198

Group type: EXPERIMENTAL
Intervention: Presence of prostatic calculi (PC) in peripheral zone (PZ) during TRUS
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Presence of prostatic calculi (PC) in transitional zone (TZ) and central zone (CZ) during TRUS
Number of subjects: 664

Group type: COMPARATOR
Intervention: Patients with prostate cancer (CaP)
Number of subjects: 664
Study: 24351403

Group type: COMPARATOR
Intervention: Placebo (no active treatment)
Number of subjects: 274
Study: 23408280

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 213
Study: 21114343

Group type: EXPERIMENTAL
Intervention: 4Rs Program
Number of subjects: 942
Study: 18249325

Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion at 5 x 10(5) KIU/h until skin closure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 16830217

Group type: EXPERIMENTAL
Intervention: PPH33-01
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PPH33-03
Number of subjects: 60
Study: 12756219

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 375
Study: 10781982

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1.5 g daily)
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Meropenem (3 g daily)
Number of subjects: 30000
Study: 8692425

Group type: EXPERIMENTAL
Intervention: Two-dimensional MRI at 1.5 T
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Two-dimensional MRI at 0.5 T
Number of subjects: 23

Group type: COMPARATOR
Intervention: CT myelography
Number of subjects: 23
Study: 1332520

Group type: EXPERIMENTAL
Intervention: Condom giveaway program
Number of subjects: 103
Study: 2866715

Group type: EXPERIMENTAL
Intervention: 0.25% betaxolol, treated twice daily for six weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo, treated twice daily for six weeks
Number of subjects: 19
Study: 31330882

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed protein (EHF) formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact protein premature formula (IPF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both EHF and IPF formulas
Number of subjects: 0
Study: 29137956

Group type: EXPERIMENTAL
Intervention: 19-Gy high-dose-rate brachytherapy (HDR-BT)
Number of subjects: 87
Study: 27460266

Group type: EXPERIMENTAL
Intervention: 2200 IU/day vitamin D3 supplementation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 1100 IU/day vitamin D3 supplementation
Number of subjects: 128

Group type: COMPARATOR
Intervention: No vitamin D supplementation (sufficient group)
Number of subjects: 128
Study: 24664858

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 15
Study: 22453250

Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LI, 30% HR reserve), n = 23
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MI, 70% HR reserve), n = 26
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (historical control, n = 45)
Number of subjects: 49
Study: 19889807

Group type: EXPERIMENTAL
Intervention: Legume-enriched, low-glycemic index diet (250 g/d, GI 38)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy American diet (high-GI, GI 69)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Legume-enriched, low-glycemic index diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy American diet
Number of subjects: 64
Study: 18947357

Group type: EXPERIMENTAL
Intervention: Unconscious thought (participants were distracted while holding the goal of solving the RAT items)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious thought
Number of subjects: 0
Study: 16952782

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1707

Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 1707
Study: 12672185

Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel®) administered subcutaneously twice weekly
Number of subjects: 1128
Study: 10827665

Group type: EXPERIMENTAL
Intervention: Transfoamwave (study mattress)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transfoam (standard hospital mattress)
Number of subjects: 100
Study: 8861666

Group type: EXPERIMENTAL
Intervention: 4-day head-down tilt (HDT; -6 degrees)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 4-day confinement
Number of subjects: 8
Study: 1516500

Group type: EXPERIMENTAL
Intervention: Morning NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Morning NPH insulin
Number of subjects: 24
Study: 6704285

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31306167

Group type: EXPERIMENTAL
Intervention: DMPA-IM
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IUD
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combined hormonal methods (DMPA-IM, norethisterone enanthate, implants)
Number of subjects: 95
Study: 28296510

Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient rehabilitation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Follow-up by a general practitioner
Number of subjects: 151
Study: 25475196

Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate 1 g just before the procedure
Number of subjects: 122

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 122
Study: 23268365

Group type: EXPERIMENTAL
Intervention: 0.5% nitroglycerine gel
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1.25% nitroglycerine gel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 37
Study: 21991568

Group type: EXPERIMENTAL
Intervention: Navigation system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (without navigation)
Number of subjects: 32
Study: 18439116

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 15
Study: 16581163

Group type: EXPERIMENTAL
Intervention: Avaxim
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intense physical activity during the first month after vaccination
Number of subjects: 97
Study: 14561059

Group type: EXPERIMENTAL
Intervention: Summer School Program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family Program
Number of subjects: 0
Study: 10758784

Group type: EXPERIMENTAL
Intervention: D‐25 (25 micrograms/day E2)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: D‐37.5 (37.5 micrograms/day E2)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 8969875

Group type: EXPERIMENTAL
Intervention: 110 Hz TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 Hz TENS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 Hz and 50 microseconds TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 Hz and 200 microseconds TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 110 Hz and 50 microseconds TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 110 Hz and 200 microseconds TENS
Number of subjects: 80